FIG 9.
Nanobody inhibition of VLP binding to PGM. In the HBGA-blocking assay, serially diluted Nano-7 (A), Nano-62 (B), or Nano-94 (C) was preincubated with GI.1 VLPs and then added to the PGM-coated wells. Nano-7 and Nano-94 blocked the binding of GI.1 VLPs to PGM in a dose-dependent manner, with IC50s of 0.43 μg/ml and 9.23 μg/ml, respectively. Nano-62 showed weak inhibition, with a maximum inhibition of 15%. The experiments were performed in triplicate (error bars shown).